Ability Pharma

MISSION Therapeutics, founded in 2011 as a spin out from the University of Cambridge, focuses on the discovery and development of small molecules that target deubiquitinating enzymes, developed using DUB-Sphere, its proprietary DUB Drug Discovery Platform, to treat cancers and other diseases.In June 2020, the company its move to new purpose-built headquarters on the Babraham Research Campus, Cambridge, UK.In February 2016, the company raised GBP 60 million (US $85.77 million) including GBP 11.3 million (US $16.15 million) from Imperial Innovations Group with GBP 3.9 million (US $5.57 million) invested in the first tranche resulting in the Group's holding increased to 21.6% interest in the company,.In November 2013, the company received GBP 20 million (US $32.2 million) in a series B funding round, of which GBP $4.5 million (US $7.25 million) was funded by Imperial Innovations Group.In August 2011, the company received GBP 6 million (US $9.87 million) in funding

Abiliity Pharmaceuticals SL (fomerly AB Therapeutics), founded in November 2009 and headquartered in Spain, is a drug discovery and development company focussed on the development of therapeutics targeting cell membranes for cancer and other indications.In September 2012, the company planned for US facilities in Boston during 2013.In December 2018, the company closed a round of financing worth more than EUR 1,230,000 (US $1,398,300) through the crowdfunding platform Capital Cell . With the figure, the company exceeded the EUR 1 million (US $1.13) with which they had opened the campaign last September, and happened to be the largest round of Capital Cell.In September 2012, the company raised EUR 1 million (US $ 1.3 million) in a second financing round.By November 2010, the company had initiated a series A financing round; in April 2015, the series A financing round of EUR 10 million (US $10.98 million) was ongoing.In October 2020 AbilityPharma receives of t

Larimar Therapeutics, Inc.是根据美国特拉华州法律于2005年11月22日注册成立。公司是一家生物制药公司，致力于显著改善因肥胖而影响身体健康的患者。 Beloranib是公司领先的候选产品，是一种新型的一级产品，用于多种适应症，包括肥胖和饮食过量的普拉德 - 威利综合症患者，与颅咽管瘤相关的肥胖，一般人群严重的母体肥胖等方面的治疗，该产品的用法是每周两次皮下注射。公司自成立以来，一直致力于研究和开发产品、招聘管理、收购经营性资产和筹集资金。因此，公司被认为是处于发展阶段。